Applied Genomics

Eyeing a commercial launch for Mammostrat in the fourth quarter of this year, Clarient highlighted publication of data further validating the test as “an aid for risk stratifying early stage hormone receptor-treated breast cancer patients."

Clarient Insight Dx Pulmotype is a five-antibody immunohistochemistry test that the company said can be used to aid in the histological distinction between adenocarcinoma and squamous cell carcinoma in NSCLC tumor specimens.

Clarient plans to commercialize Applied Genomics' five-antibody immunohistochemistry test for non-small cell lung cancer, called Pulmotype, within its network of pathologists by the first quarter of 2010.

Applied Genomics is gearing up to launch a lung cancer diagnostic panel intended to help physicians make treatment decisions.

People In the News

Lai Named SVP of R&D at Gen-Probe, Jorge Leon Joins ParagonDx SAB, Strategic Diagnostics Hires Two Execs, and More.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.